Triose phosphate isomerase 1 in serum of women with breast cancer

Introduction

Triosephosphate isomerase 1 (TPI1) plays a role in various biological processes, specifically in the development of the metastatic phenotype, and is recognized as a significant enzyme in the glucose metabolism pathway. TPI1 has been proposed as a potential oncogene, with several types of cancer including breast cancer (BC).

Material

This research aims to assess activity of TPI1 in serum samples obtained from female subjects with BC. The levels of TPI1 were evaluated in the serum samples of four different BC groups, with 54 women included as the control group.

Results

Based on the findings, the average TPI levels were (41.01 ± 7.92) and (11.91 ± 2.68) in BC patients and healthy controls, respectively. The mean level higher in BC patients compared to healthy controls (P < .001). Additionally, the serum TPI1 levels in group IV showed a significant increase (P < .0001) compared to groups I, II, and III. Analysis of both univariate and multivariate models indicated that age (odds ratio [OR] = 1.12, 95% confidence interval [CI] = 0.76–8.12, P < .01) and TPI1 levels (OR = 4.1, 95% CI = 4.31–26.71, P = .001) were identified as independent predictors for the presence of malignancy. Furthermore, receiver operating characteristic analysis demonstrated a high diagnostic accuracy for TPI concentrations, with an area under the curve value of 0.999.

Conclusion

The levels of serum TPI1 have been observed to increase in patients diagnosed with BC. There is a correlation between the concentration of TPI1 and the presence of breast malignancy.